The standard GHK-Cu injection frequency is once daily, five days on and two days off, for 4 to 12 weeks followed by a 2 to 4 week break
Muniyappa did not respond to requests for comment
Diabetes type 2 has a high prevalence in the obese (BMI 25kg/m 2 ) and overweight (BMI 30kg/m 2 ) population, and these patients tend to have poor diets and sedentary lifestyles
Which sort of doesnt make sense because you know, this, as soon as products lose their patent and generic molecule, especially small molecules are introduced in the market, not like biosimilars, the market collapses, and these prices of these drugs, bought them out at 90% reduction
"Novo Nordisk announces FDA approval of label update for Rybelsus (semaglutide) allowing use as a first-line option for adults with type 2 diabetes" (Press release)
Benton D, Donohoe R